Advances in hypertension and diabetes in 2007;Temas de actualidad en hipertensión arterial y diabetes

Revista Espanola de Cardiologia

Volumn 61, Issue SUPPL. 1, 2008, Pages 58-71

  Mazón Ramos, Pilar ^a   Martínez, Vicente Bertomeu ^b   Granado, Juan Quiles ^b   González Juanatey, José R ^a  

^a University Hospital of Santiago de Compostela   (Spain)

^b HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

Author keywords

ADVANCE trial; Clinical practice guidelines; Diabetes; Hypertension; Rosiglitazone

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIBENCLAMIDE PLUS METFORMIN; GLITAZONE DERIVATIVE; INDAPAMIDE; INSULIN; METFORMIN; PERINDOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ARTERIAL PRESSURE; DIABETES MELLITUS; DRUG EFFECT; ELECTROCARDIOGRAM; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MEDICAL SOCIETY; PRACTICE GUIDELINE; REVIEW; STABLE ANGINA PECTORIS; SYSTOLIC BLOOD PRESSURE;

EID: 46449084397     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13114958     Document Type: Article

References (18)

1. Ezzati M, Lopez AD, Rodgers A, Vander HS, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-60.
2. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
3. Mancia G, De Baker G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007. Rev Esp Cardiol. 2007;60:968.e1-94.
4. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo J, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761-88.
5. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, De Boer MJ, et al. Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares. Rev Esp Cardiol. 2007;60:525.e1-e64.
6. González-Juanatey JR, Alegría-Ezquerra E, Aznar-Costa J, Bertomeu-Martínez V, Franch-Nadal J, et al. Conocimiento y aplicación de las guías de práctica clínica sobre riesgo cardiovascular en las consultas generales y especializadas. Rev Esp Cardiol. 2006;59:801-6.
7. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89.
8. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49:1772-80.
9. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-105.
10. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-43.
11. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-71.
12. Rosen CJ. The rosiglitazone story: lessons from an FDA Advisory Committee Meeting. N Engl J Med. 2007;357:844-6.
13. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone. JAMA. 2007; 298: 1189-95.
14. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomised trials. JAMA. 2007;298:1180-8.
15. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Evolución de la enfermedad coronaria en pacientes tratados con fármacos antidiabéticos. Pharmacoepidemiol Drug Saf. 2007;16:711-25.
16. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk fro myocardial infarction and cardiovascular death. Ann Intern Med. 2007 (Epub ahead of print).
17. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al, for the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes; an interim analysis. N Engl J Med. 2007;357:8-38.
18. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-40.